Published June 21, 2018 | Version v1
Patent Open

CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2

  • 1. University of Chicago
  • 2. Baylor College of Medicine

Contributors

Description

Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).

Files

US20180170992.pdf

Files (6.2 MB)

Name Size Download all
md5:7c3e1c73570b36bd01bedecc77583688
6.2 MB Preview Download

Additional details

Identifiers

Patent application number
US 201615545950 A
Patent number
US 2018/0170992 A1
Other
oai:uchicago.tind.io:8520

Dates

Patent filed
2016-01-26

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Neurological Surgery, Medicine